The estimate is of FarmaBrasil, an organization that represents how laboratories Aché, Biolab, Bionovis, Cristália, EMS and Eurofarma, based on his associates. The change will bring legal certainty in developing drugs made from medicinal plants found in Brazil and more quickly to the release.
Today, the authorization for the beginning of clinical research takes about four years. With the new benchmark, companies need only to a record autodeclaratório. "In addition to the industries that interrupted the development of new drugs, there are also laboratories that are not yet in that market, but who want to enter," said Reginaldo Arcuri, President of the entity.
The Biolab resumed six projects that were stopped, which will require around $ 120 million in contributions. "We are being sought after by companies interested in developing drugs together, what before was not," says Dante Alário, Managing Director of Biolab.
The Group wants to expand from 3% to 15% of segment revenue participation in up to six years.
END OF GREY ZONE
The Aché lab has about 20 projects of herbal medicines mapped that should begin to be developed with the sanction of the new landmark. Each remedy may require between $ 15 million and $ 20 million in contributions for its creation.
"The legal framework will give us the security to invest without fear of finding any obstacle ahead, and also the cost forecast drug development", says Paulo Nigro, President of the company. Today, the Aché has four or five herbal remedies in creation phase, but made from medicinal plants from other countries.
The segment accounts for 5% to 7% of the company's revenue. The estimate is that it represents between 10% and 20% in the next ten years, according to the Executive. "The Brazil has the highest biodiversity in the world. The law brings the possibility of national industries have global competitiveness. "
Folha de S Paulo
Related products
News Item translated automatically
Click HERE to see original
